Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2024 Jan 5.

Published in final edited form as: Clin Cancer Res. 2023 Jul 5;29(13):2394–2400. doi: 10.1158/1078-0432.CCR-23-0036

Table 1.

Baseline Characteristics of Patient Population


Patients, N (%)		20 (100)

Sex, N (%)	Female	9 (45)

ECOG performance status, N (%)	0	11 (55)
ECOG performance status, N (%)	1	9 (45)

Age, years	Median (range)	65 (43–75)

Race/Ethnicity, N (%)	White, Non-Hispanic	15 (75)
	White, Hispanic	2 (10)
	Asian	1 (5)
	Not reported	2 (10)

Anatomic subtype, N (%)	Extrahepatic, Distal	2 (10)
	Extrahepatic, Hilar	6 (30)
	Gallbladder	3 (15)
	Intrahepatic	9 (45)

Disease extent, N (%)	Locally Advanced	5 (25)
Disease extent, N (%)	Metastatic	15 (75)

Prior therapy, N (%)	Radiotherapy	3 (15)
Prior therapy, N (%)	Surgery	7 (35)

CA 19–9 at baseline, U/mL	Median (range)	170.5 (58.5 – 1357)

CA 19–9, carbohydrate antigen 19–9; ECOG, Eastern Cooperative Oncology Group